Regular monitoring of inflammatory markers, disease activity scores, and functional status remains essential regardless of concurrent GLP-1 use
A dedicated formula like Liposomal Glutathione is designed to support that kind of routine
A significant improvement in MASH without worsening of fibrosis was reported at a subcutaneous dose of 0.4 mg [80]
Cardiovasc Hematol Agents Med Chem 16(1):3543 Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ (2020) Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis